Drug Discovery

Pfizer’s GBS6 receives FDA Breakthrough Therapy Designation

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s GBS6 or PF-06760805 to prevent invasive Group B Streptococcus (GBS) disease in new-borns and infants through immunisation of women during pregnancy.

Bristol Myers Squibb acquires Turning Point for $4.1bn

Bristol Myers Squibb has completed the previously announced acquisition of Turning Point Therapeutics, for a total consideration of $4.1bn in cash.

Senda raises funds to advance programmable medicines platform development

Senda Biosciences has raised $123m in Series C financing round to advance the development of its programmable medicines’ platform into clinical testing.

Epigenic Therapeutics secures funds to advance gene editing therapy

Chinese biotechnology firm Epigenic Therapeutics has secured $20m in Series Angel and Pre-A funding to proceed with next-generation gene editing therapy.

TransCode and MD Anderson partner to advance RNA-targeted cancer therapies

TransCode Therapeutics has entered into a strategic alliance with the University of Texas MD Anderson Cancer Center for advancing its RNA therapies for oncology.

BridGene raises $38.5m to develop IMTAC platform and cancer drugs

BridGene Biosciences has raised $38.5m in Series B financing round for the development of its next generation chemoproteomic platform, Isobaric Mass Tagged Affinity Characterization (IMTAC), as well as oncology drugs.

QBiotics receives IND application approval for Phase II solid tumours therapy trial

The US Food and Drug Administration (FDA) has approved QBiotics Group’s Investigational New Drug (IND) application to commence the Phase II clinical trial (QB46C-H07) of tigilanol tiglate.

SRI, Amylyx Pharmaceuticals partner to identify ALS drug candidates

Sunnybrook Research Institute (SRI) and Amylyx Pharmaceuticals have joined forces to develop new drug candidates to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

SK Biopharmaceuticals, Eurofarma sign deal for epilepsy therapy

SK Biopharmaceuticals and Brazilian pharmaceutical firm Eurofarma have signed a license agreement to develop and commercialise cenobamate to treat epilepsy in Latin America.